Overview of Dr. Awad
Dr. Mark Awad is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center, Brigham and Women's Hospital, and Dana-Farber Cancer Institute. He received his medical degree from Johns Hopkins University School of Medicine and has been in practice 9 years. He is one of 376 doctors at Brigham and Women's Hospital and one of 450 doctors at Dana-Farber Cancer Institute who specialize in Oncology. He has more than 100 publications and over 500 citings.
Office
530 E 74th St
New York, NY 10021Fax+1 929-321-8179
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2011 - 2014
Massachusetts General HospitalResidency, Internal Medicine, 2008 - 2011
Johns Hopkins University School of MedicineClass of 2008
Certifications & Licensure
NY State Medical License 2024 - 2026
MA State Medical License 2012 - 2025
NJ State Medical License 2024 - 2025
NH State Medical License 2024 - 2024
RI State Medical License 2020 - 2020- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Merestinib In Non-Small Cell Lung Cancer And Solid Tumors Start of enrollment: 2016 Nov 11
- A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma Start of enrollment: 2017 Apr 10
- A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer Start of enrollment: 2017 Jun 19
- Join now to see all
Publications & Presentations
PubMed
- 49 citationsClinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer.Adam J. Schoenfeld, Scott J. Antonia, Mark M. Awad, Enriqueta Felip, Justin F. Gainor
Annals of Oncology. 2021-09-03 - 50 citationsLow peripheral blood derived neutrophil-to-lymphocyte ratio (dNLR) is associated with increased tumor T-cell infiltration and favorable outcomes to first-line pembroli...Joao Victor Machado Alessi, Biagio Ricciuti, S. Alden, Arrien A. Bertram, Jessica J. Lin
Journal for Immunotherapy of Cancer. 2021-11-01 - 625 citationsThe ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non–Small Cell Lung CancerLuc Friboulet, Nanxin Li, Ryohei Katayama, Christian C. Lee, Justin F. Gainor
Cancer Discovery. 2014-03-27
Journal Articles
- Authors’ ResponseMatthew P Cheng, Mark M Awad, Journal of Thoracic Oncology
Lectures
- Phase Ib study: Selective histone deacetylase (HDAC) inhibitor ACY-241 + nivolumab (Nivo) in advanced non-small cell lung cancer (NSCLC).2019 ASCO Annual Meeting - 6/1/2019
- Mechanisms of acquired resistance to MET tyrosine kinase inhibitors (TKIs) in MET exon 14 (METex14) mutant non-small cell lung cancer (NSCLC).2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
- ECHO-305/KEYNOTE-654: A phase 3, randomized, double-blind study of first-line epacadostat plus pembrolizumab vs pembrolizumab plus placebo for metastatic non small cel...2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
Authored Content
- Authors’ ResponseOctober 2018
Press Mentions
Questions to Ask if You've Been Diagnosed with Lung CancerNovember 1st, 2024- New Study to Address Cancer Treatment Resistance for People Who Are KRAS PositiveNovember 30th, 2022
- Opdivo May Bring Survival Boost for Lung Cancer PatientsApril 13th, 2022
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
